The brand-new unit will have a BSL3 facility for the manufacture of drug substances and a fill-finish capability for the production of both drug products FMD vaccine and the FMD+HS vaccine.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iLcnVFd
via IFTTT
No comments:
Post a Comment